In IBD, serious infectious complications are more common in patients treated with IFX and corticosteroids separately,34 35 and in combination.36 Other studies have observed variable rates of infectious complications in CPI-treated patients receiving combination anti-TNF and corticosteroid treatment, ranging between 0%37 and 24%.30 Our data argue strongly in favor of prospective randomized controlled trials and we note that a head to head study of IFX against vedolizumab is currently recruiting (ClinicalTrials.gov Identifier: NCT04407247). This evidence concerns the gene TNF and inflammatory bowel disease.